Skip to the reading

[Peptide Studies](/)

[Study leaves](/tirzepatide) [The sources](/references) [Our approach](/about)

We read peptide research one study at a time, keeping what happened beside what remains unshown.

- [Peptide Studies](/)
- Tirzepatide

# The tirzepatide result belongs to the people who were studied.

Tirzepatide produced a large average weight loss in this trial. We want to keep the people and the comparison beside that result, so it stays useful when you read it.

03

## A weight trial with a defined group

![Lower legs of an anonymous adult standing neutrally on a plain household scale, with its display hidden from view.](/study-leaves-3d0d256cd049/tirzepatide-meal.webp)

The scale makes the measured outcome plain: body weight. This illustrative scene isn't a photograph of a participant or a claim about the result anyone will get.

The [72-week tirzepatide trial](https://pubmed.ncbi.nlm.nih.gov/35658024/) included adults with obesity, or overweight with a related health condition. They didn't have diabetes. That tells us who the finding is about.

Chance assigned people to three tirzepatide groups or a placebo, a dummy treatment. Participants and the researchers assessing treatment didn't know who had the active medicine. That's what double-blind means here.

People receiving tirzepatide lost about 15% to 21% of their starting weight on average, depending on the study group. The placebo group lost about 3%. Those are substantial differences, even with the comparison kept in view.

The averages don't tell us what happened to every person. That top figure is easy to remember, but it belongs to one group. Reading it as your likely result would give the number a job it can't do.

Regular visits and lifestyle counselling were part of the trial too. We keep them in the story because the study tested the medicine in that setting. It wasn't a test of taking a medicine with no surrounding care.

Digestive problems were the most common side effects. They were mostly mild or moderate and often happened as treatment was increased. That describes the study experience; it doesn't mean stomach trouble is always minor.

The [prescribing information warns about severe digestive problems](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b) and kidney injury linked to fluid loss. It also says the medicine isn't recommended for severe gastroparesis, where the stomach empties very slowly. These warnings matter alongside the weight finding.

FDA-approved tirzepatide products exist. A licensed U.S. clinician can discuss whether an approved treatment fits your situation. This paper can help you bring a clearer question to that conversation, rather than decide the answer for you.

### What this did not show

This trial didn't compare tirzepatide directly with semaglutide. Putting numbers from separate trials side by side doesn't create that comparison. It also doesn't tell us what happens after treatment stops or settle safety over a lifetime.

We'd carry away the comparison: a large average weight change over 72 weeks in adults without diabetes, with regular support. That's a useful finding. It still leaves room for a different answer about one person's care.

[Read the smaller retatrutide trial](/retatrutide)

[Opening accounts](/#study-accounts) [Retatrutide](/retatrutide) [Tesamorelin](/tesamorelin) [PT-141](/pt-141) [References](/references) [About](/about) [Contact](/contact)

Peptide Studies is a place to read a paper carefully—a guide to the research, never a clinic, pharmacy or seller.

© 2026 Peptide Studies